Berlin will see a new push for practical manufacturing at Cell and Gene Therapy International Europe 2026. The event runs at Hotel Palace Berlin from 3 to 5 November 2026. This year, the program grows. Two new streams—Exosomes Europe and LNPs Europe—join the main agenda. The BioXconomy Events calendar lists all three for the same dates and venue. The scope is bigger. The focus is clear.
Three streams. Two days. Attendees will have to move fast. The schedule is packed. Organizers promise less theory, more action. Sessions will drill into how to cut costs and boost output for Advanced Therapy Medicinal Products. The independent event calendar calls Cell & Gene Therapy International Europe a forum for real manufacturing problems, regulatory hurdles, and getting products to market. The shift is obvious. Manufacturing and scale-up now take center stage.
Exosomes Europe is returning for its second edition in Berlin, emphasizing a community-driven format and signaling sustained interest in extracellular vesicle applications.
Adding Exosomes Europe and LNPs Europe is no accident. These streams target the delivery systems and tech shaping the next wave of cell and gene therapies. By running them together, organizers want ideas to cross over. The goal is simple. Get progress out of the lab and onto the factory floor. Promotional materials for Exosomes Europe say it straight: "bridge the gap between discovery and commercial reality" and move extracellular vesicle (EV) pipelines to patients. The message matches the event’s bigger theme—commercialization and getting ready to manufacture at scale.
The tight schedule means tough choices. Attendees must pick what matters most. The event’s design matches the industry’s reality. Time, efficiency, and cost are daily battles for every advanced therapies company. This is not theory. It’s survival. The focus lands as Germany’s biopharma and advanced therapies sector keeps changing. Medios, for example, finished its manufacturing network overhaul and stopped all Advanced Therapies work in September 2026. The reason is simple. Economic pressure is rising.
Medios publicly announced on 29 September 2026 that it has completed the optimization of its manufacturing network and ceased activities in Advanced Therapies, reflecting ongoing economic pressures in the German advanced therapies segment.
Cell and Gene Therapy International Europe 2026 aims to be the place where real bottlenecks meet real fixes. Berlin is not just a backdrop. The city’s biotech scene is growing. Organizers want to draw a European and global crowd that cares about execution, not just ideas. For advanced therapy manufacturing, Berlin is the place to be this year. The center of gravity just shifted.
